EVENTS | VIEW CALENDAR
75 different translations
SALT LAKE CITY—With the goal of easing data management burdens in clinical research, RemedyMD Inc. and GulfStream Bioinformatics Corp., providers of clinical and translational research solutions, have partnered to provide researchers with a suite of software applications that will standardize data integration.
As part of the partnership, RemedyMD will incorporate GulfStream's DiseaseLink Knowledge Base and Biomaterials and Information for Genomics Research (BIGR) into its Investigate research software suite. The synergized software will enable research teams to start with a pre-built registry that is already populated with relevant disease-specific data elements and further their research using a suite of applications and tools designed to eliminate data management burdens.
"We came together with RemedyMD because their applications, platforms and experience with phenotype data management, together with our disease models and tools for managing biospecimens—the systems needed to effectively link the phenotype data and genotype data—make the combined solutions very compelling for the market," says Howard Greenman, vice president of Business Development and Client Services at GulfStream. "A common interest in understanding the requirements of researchers led us into the same circles and we quickly realized we have complimentary capabilities."
Emily Bonham, senior director of Product Management at RemedyMD, says although today's technology has enabled researchers to use spreadsheets and databases such as Microsoft Excel and Access to store data electronically, it still has not addressed the major pains of researchers and research organizations.
"GulfStream identified that with GulfStream's genotypic disease elements and RemedyMD's platform, applications, tools and phenotypic data elements, we could provide the ultimate pre-built solution for researchers," Bonham says. "These systems can handle not only multiple disease types, but they can also be customized by the individual researchers for their specific data collection and reporting needs."
Investigate is designed to allow researchers to coordinate data from all elements and team members involved in the execution of studies, allowing them to merge and standardize previously collected data sets while aggregating all study data in a common, standardized repository.
"Investigate can address all the researchers' pain points such as collaboration across one or many institutions, customizable data collection, terminology mapping, data aggregation and robust reporting," Bonham says. "Because Investigate makes it so easy to report on any data element in any combination with other data elements, researchers can quickly see trends within their drug studies that can lead to new discoveries of alternative drug indications. Using Investigate's genotypic and phenotypic data elements in conjunction with the robust reporting tools, researchers can pinpoint genetic variations that are leading to adverse drug events and differences in drug response between populations."
Ultimately, the two companies hope their synergized software applications will help researchers more efficiently find relationships between phenotype and genotype data, which may lead to discoveries of how drugs work differently in different sub-populations of a particular disease, Greenman says.
"In addition, our combined tools will help in development by leading to more efficient deployment of molecular-based clinical trials, where the collection of biospecimens and the ability to make faster and better decisions about the course of such trials is dependent on getting consistent, high-quality specimens and associated data, and having the tools to optimally access and manage that data," he says.